Cyprus

Cyprus appears to have a restrictive access environment for classical psychedelics, with no routine authorised medical use outside clinical research or exceptional controlled-drug pathways. Blossom currently links one ketamine-based trial in the country and no active linked trials, stakeholders or events, which is consistent with a small visible psychedelic research footprint.

Ask Blossom about this country

Data updated July 15, 2026

Key Insights

A concise view of the policy, research, access, and stakeholder details shaping psychedelic medicine inCyprus.

1
The country's psychedelic ecosystem is small and research-led rather than access-led, with ketamine the main clinically relevant compound in the linked evidence base.
2
A University of Cyprus ketamine/OUD trial indicates local scientific interest in substance-use treatment, but Blossom's linked-trial count remains very limited.
3
Controlled-drug administration appears to run through formal Ministry of Health permissions, which suggests that access depends more on regulation and licensing than on a broad clinic market.
4
Cyprus's public health and pharmaceutical structures are present, but the visible evidence does not support routine authorised use of psilocybin, MDMA or similar classical psychedelics.
5
The main uncertainty is practical access rather than the existence of a hard regulatory framework: the published material supports tight control, but not any broad patient-access pathway for psychedelic medicines.

Research and Access Snapshot

Blossom currently tracks 1 psychedelic clinical trial connected to Cyprus.

Active trials: 0
Total trials: 1
Stakeholders: 1
Events: 0

Top Compounds

Ketamine(1)

Medical Access

Cyprus maintains a restrictive statutory regime for classical psychedelics (psilocybin, MDMA, DMT, mescaline, most tryptamines and phenethylamines) with no routine authorised medical use outside clinical research. Ketamine is used clinically (including in research) and esketamine (Spravato) is authorised across the EU - access and public reimbursement in Cyprus is limited and dependent on national formulary / HIO (GeSY) decisions or private-pay arrangements and specialised clinic availability.

View trials→View stakeholders→Open access guide→

Regulatory Status

Cyprus's Ministry of Health treats narcotics and psychotropics as controlled substances subject to permits and import/export licensing, and travellers or patients carrying controlled medicines need formal authorisation. Public-facing Ministry and EU-linked material indicate that cross-border or personal-use dispensing is restricted for controlled medicines, so classical psychedelics are best understood as tightly controlled and not routinely available as treatments; any use beyond research or exceptional permissions should be assumed uncertain unless directly licensed.